Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (351-360 of 456) with videos related to

Pageof 46
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2017
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose LevelsPaolo G Casali, John Zalcberg, Axel Le Cesne, et al.
Insights Into Imaging|June 14, 2025
Diagnostic work-up of lipomatous tumors: a decision-making analysis among European sarcoma centersAli Naimi, Paul Martin Putora, Christian Rothermundt, et al.
The Lancet. Oncology|February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 studyReinhard Dummer, Jun Guo, Jason J Luke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 StudyJason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.
The New England Journal of Medicine|January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaHussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
Annals of Surgical Oncology|June 14, 2013
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experiencePiotr Rutkowski, Alessandro Gronchi, Peter Hohenberger, et al.
JAMA Surgery|April 3, 2020
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant ImatinibAlessandro Gronchi, Sylvie Bonvalot, Andres Poveda Velasco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on SarcomasPaolo G Casali, Axel Le Cesne, Andres Poveda Velasco, et al.
Annals of Surgery|July 14, 2022
Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) ResultsDario Callegaro, Chandrajit P Raut, Taiwo Ajayi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2023
Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective AnalysisJuergen Hench, Daniela Mihic-Probst, Abbas Agaimy, et al.
Pageof 46

Showing results (351-360 of 456) with videos related to

Sort By:
Pageof 46
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2017
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose LevelsPaolo G Casali, John Zalcberg, Axel Le Cesne, et al.
Insights Into Imaging|June 14, 2025
Diagnostic work-up of lipomatous tumors: a decision-making analysis among European sarcoma centersAli Naimi, Paul Martin Putora, Christian Rothermundt, et al.
The Lancet. Oncology|February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 studyReinhard Dummer, Jun Guo, Jason J Luke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 StudyJason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.
The New England Journal of Medicine|January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaHussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
Annals of Surgical Oncology|June 14, 2013
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experiencePiotr Rutkowski, Alessandro Gronchi, Peter Hohenberger, et al.
JAMA Surgery|April 3, 2020
Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant ImatinibAlessandro Gronchi, Sylvie Bonvalot, Andres Poveda Velasco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on SarcomasPaolo G Casali, Axel Le Cesne, Andres Poveda Velasco, et al.
Annals of Surgery|July 14, 2022
Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) ResultsDario Callegaro, Chandrajit P Raut, Taiwo Ajayi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2023
Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective AnalysisJuergen Hench, Daniela Mihic-Probst, Abbas Agaimy, et al.
Pageof 46